Details

Autor(en) / Beteiligte

• Langley, Richard G
• Elewski, Boni E
• Lebwohl, Mark
• Reich, Kristian
• Griffiths, Christopher E.M
• Papp, Kim
• Puig, Lluís
• Nakagawa, Hidemi
• Spelman, Lynda
• Sigurgeirsson, Bárður
• Rivas, Enrique
• Tsai, Tsen-Fang
• Wasel, Norman
• Tyring, Stephen
• Salko, Thomas
• Hampele, Isabelle
• Notter, Marianne
• Karpov, Alexander
• Helou, Silvia
• Papavassilis, Charis

Titel

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Ist Teil von

• The New England journal of medicine, 2014-07, Vol.371 (4), p.326-338

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In two trials in patients with moderate-to-severe plaque psoriasis, the anti–interleukin-17A monoclonal antibody secukinumab was more effective than placebo and etanercept. Infectious complications occurred more often with secukinumab than with placebo. Psoriasis is a chronic, immune-mediated inflammatory skin disease that is associated with substantial impairment of physical and psychological quality of life. 1 , 2 Our understanding of the pathogenesis of psoriasis was advanced by the discovery of the class of type 17 helper T (Th17) cells, which regulates innate and adaptive immunity. The proinflammatory cytokine interleukin-17A is the primary effector of Th17 cells, but it is also produced by other cell types in psoriatic lesions, including γδ T cells, neutrophils, and possibly mast cells. 3 – 7 Interleukin-17A stimulates keratinocytes to secrete chemokines and other proinflammatory mediators that recruit additional inflammatory cells, including neutrophils, . . .